Lymphocytotoxic autoantibodies

Yves Renaudineau, M. Eric Gershwin, Pierre Youinou

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Patients with systemic lupus erythematosus (SLE) develop anti-lymphocytotoxic antibodies (anti-LCA) measured by complement-dependent cytotoxicity assay (CDCC). In SLE, prevalence is ranging from 60 to 90% and varies according to the methods of detection and definition of test positivity. Lymphocytotoxic antibodies (LCA) have been shown to bind to several targets on lymphocytes. CD45 represent the main LCA target. Anti-ribosome P0 and antiβ2 microglobulin antibodies have been included in the spectrum of LCA. Binding to lymphocytes may vary according to the T- or B-cell subsets, to the activation state, which is the consequence of CD45 isoform variations in these cells. The pathogenic role of LCA on lymphopenia was not clearly established in vivo. Nevertheless, in vitro LCA may induce apoptosis, CDCC, and cell activation with cytokine production suggesting that LCA have the potential to influence lymphocyte functions. High titers of both IgM and IgG classes occur during phases of active nephritis and neurological lupus. Finally, LCA are reported also in quite a lot of other diseases such as Sjögren's syndrome, rheumatoid arthritis, cancer and infections. An increased incidence of LCA in consanguineous from lupus patients is described suggesting that this autoantibodies are genetically controlled.

Original languageEnglish (US)
Title of host publicationAutoantibodies
PublisherElsevier Inc.
Pages537-543
Number of pages7
ISBN (Print)9780444527639
DOIs
StatePublished - 2007

Fingerprint

Antilymphocyte Serum
Autoantibodies
Lymphocytes
Cytotoxicity
Systemic Lupus Erythematosus
Assays
Chemical activation
B-Lymphocyte Subsets
Lymphopenia
Lupus Nephritis
Ribosomes
Immunoglobulin M
Anti-Idiotypic Antibodies
Rheumatoid Arthritis
Protein Isoforms
Immunoglobulin G
Cells
Apoptosis
Cytokines
Antibodies

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Renaudineau, Y., Gershwin, M. E., & Youinou, P. (2007). Lymphocytotoxic autoantibodies. In Autoantibodies (pp. 537-543). Elsevier Inc.. https://doi.org/10.1016/B978-044452763-9/50070-6

Lymphocytotoxic autoantibodies. / Renaudineau, Yves; Gershwin, M. Eric; Youinou, Pierre.

Autoantibodies. Elsevier Inc., 2007. p. 537-543.

Research output: Chapter in Book/Report/Conference proceedingChapter

Renaudineau, Y, Gershwin, ME & Youinou, P 2007, Lymphocytotoxic autoantibodies. in Autoantibodies. Elsevier Inc., pp. 537-543. https://doi.org/10.1016/B978-044452763-9/50070-6
Renaudineau Y, Gershwin ME, Youinou P. Lymphocytotoxic autoantibodies. In Autoantibodies. Elsevier Inc. 2007. p. 537-543 https://doi.org/10.1016/B978-044452763-9/50070-6
Renaudineau, Yves ; Gershwin, M. Eric ; Youinou, Pierre. / Lymphocytotoxic autoantibodies. Autoantibodies. Elsevier Inc., 2007. pp. 537-543
@inbook{04bafcaba1064bbf87ac2efaedb830b5,
title = "Lymphocytotoxic autoantibodies",
abstract = "Patients with systemic lupus erythematosus (SLE) develop anti-lymphocytotoxic antibodies (anti-LCA) measured by complement-dependent cytotoxicity assay (CDCC). In SLE, prevalence is ranging from 60 to 90{\%} and varies according to the methods of detection and definition of test positivity. Lymphocytotoxic antibodies (LCA) have been shown to bind to several targets on lymphocytes. CD45 represent the main LCA target. Anti-ribosome P0 and antiβ2 microglobulin antibodies have been included in the spectrum of LCA. Binding to lymphocytes may vary according to the T- or B-cell subsets, to the activation state, which is the consequence of CD45 isoform variations in these cells. The pathogenic role of LCA on lymphopenia was not clearly established in vivo. Nevertheless, in vitro LCA may induce apoptosis, CDCC, and cell activation with cytokine production suggesting that LCA have the potential to influence lymphocyte functions. High titers of both IgM and IgG classes occur during phases of active nephritis and neurological lupus. Finally, LCA are reported also in quite a lot of other diseases such as Sj{\"o}gren's syndrome, rheumatoid arthritis, cancer and infections. An increased incidence of LCA in consanguineous from lupus patients is described suggesting that this autoantibodies are genetically controlled.",
author = "Yves Renaudineau and Gershwin, {M. Eric} and Pierre Youinou",
year = "2007",
doi = "10.1016/B978-044452763-9/50070-6",
language = "English (US)",
isbn = "9780444527639",
pages = "537--543",
booktitle = "Autoantibodies",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Lymphocytotoxic autoantibodies

AU - Renaudineau, Yves

AU - Gershwin, M. Eric

AU - Youinou, Pierre

PY - 2007

Y1 - 2007

N2 - Patients with systemic lupus erythematosus (SLE) develop anti-lymphocytotoxic antibodies (anti-LCA) measured by complement-dependent cytotoxicity assay (CDCC). In SLE, prevalence is ranging from 60 to 90% and varies according to the methods of detection and definition of test positivity. Lymphocytotoxic antibodies (LCA) have been shown to bind to several targets on lymphocytes. CD45 represent the main LCA target. Anti-ribosome P0 and antiβ2 microglobulin antibodies have been included in the spectrum of LCA. Binding to lymphocytes may vary according to the T- or B-cell subsets, to the activation state, which is the consequence of CD45 isoform variations in these cells. The pathogenic role of LCA on lymphopenia was not clearly established in vivo. Nevertheless, in vitro LCA may induce apoptosis, CDCC, and cell activation with cytokine production suggesting that LCA have the potential to influence lymphocyte functions. High titers of both IgM and IgG classes occur during phases of active nephritis and neurological lupus. Finally, LCA are reported also in quite a lot of other diseases such as Sjögren's syndrome, rheumatoid arthritis, cancer and infections. An increased incidence of LCA in consanguineous from lupus patients is described suggesting that this autoantibodies are genetically controlled.

AB - Patients with systemic lupus erythematosus (SLE) develop anti-lymphocytotoxic antibodies (anti-LCA) measured by complement-dependent cytotoxicity assay (CDCC). In SLE, prevalence is ranging from 60 to 90% and varies according to the methods of detection and definition of test positivity. Lymphocytotoxic antibodies (LCA) have been shown to bind to several targets on lymphocytes. CD45 represent the main LCA target. Anti-ribosome P0 and antiβ2 microglobulin antibodies have been included in the spectrum of LCA. Binding to lymphocytes may vary according to the T- or B-cell subsets, to the activation state, which is the consequence of CD45 isoform variations in these cells. The pathogenic role of LCA on lymphopenia was not clearly established in vivo. Nevertheless, in vitro LCA may induce apoptosis, CDCC, and cell activation with cytokine production suggesting that LCA have the potential to influence lymphocyte functions. High titers of both IgM and IgG classes occur during phases of active nephritis and neurological lupus. Finally, LCA are reported also in quite a lot of other diseases such as Sjögren's syndrome, rheumatoid arthritis, cancer and infections. An increased incidence of LCA in consanguineous from lupus patients is described suggesting that this autoantibodies are genetically controlled.

UR - http://www.scopus.com/inward/record.url?scp=84882538591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882538591&partnerID=8YFLogxK

U2 - 10.1016/B978-044452763-9/50070-6

DO - 10.1016/B978-044452763-9/50070-6

M3 - Chapter

SN - 9780444527639

SP - 537

EP - 543

BT - Autoantibodies

PB - Elsevier Inc.

ER -